Plantar Fasciopathy: Why the Calf Belongs in Your Treatment Plan

A middle-aged runner walks into clinic complaining of a stabbing pain under the medial calcaneus on the first step out of bed. She has been told by three previous practitioners that she has “plantar fasciitis,” she has had two cortisone injections in twelve months, and she is bewildered that stretching the fascia against a wall has done nothing useful. She wants to know what she is doing wrong.

The honest answer, in most of these consultations, is: not much. The model she was sold is wrong.

Plantar heel pain in this country is also less rare in elite contact-sport populations than the literature suggests. Jack Viney (Melbourne, 2017) had a surgical fascial release for a long-standing fasciopathy carried through most of a season. Jason Taumalolo (North Queensland, 2019) tore part of his plantar fascia in Round 21 and played the back end of the season through it. Joe Moody (Crusaders / All Blacks, 2021) was ruled out for four to five months and required surgery after a plantar fasciitis episode that ended his Super Rugby season in his hundredth game. Different sports, different anthropometries, the same enthesopathy. It belongs on the differential in any midfield, lock or front-row player presenting with first-step heel pain, not only in the long-distance runner archetype.

Terminology: the -itis problem

The word plantar fasciitis survives because clinicians are used to it and patients can Google it. Histologically it is misleading. Lemont, Ammirati and Usen’s biopsy series of 50 cases at the time of fascial release surgery found myxoid degeneration, fragmentation of fascia, and absent or sparse inflammatory cells.¹ Wearing and colleagues, in their 2006 Sports Medicine review of the pathomechanics, describe a non-inflammatory degenerative enthesopathy with disordered collagen and increased ground substance.² The disease behaves like a tendinopathy, not a tenosynovitis. The Brukner & Khan editorial line — that -itis terminology drives bad treatment — applies here exactly as it does at the Achilles. The label invites NSAIDs and injections that target a process that mostly is not happening.

The 2023 JOSPT Heel Pain Clinical Practice Guideline (Koc et al.) preserves plantar fasciitis as the working diagnostic label but treats it as a tendinopathy-style overload condition, not an inflammatory one.³ That is the right pragmatic compromise. For our writing here we will use plantar fasciopathy — the more accurate term, and the one this article series uses consistently.

What the 2023 CPG actually says

The Koc et al. revision is the most useful single document for clinicians treating heel pain in 2026. Three things stand out.

First, the differential. The guideline opens by reminding us that plantar heel pain is an umbrella label that includes plantar fasciopathy, heel fat pad syndrome, calcaneal stress reaction, Baxter’s nerve (first branch of the lateral plantar nerve) entrapment, tarsal tunnel syndrome and proximally referred S1 radiculopathy. The CPG endorses an active screening process. Diagnosis is not “tender at the calcaneal tuberosity, therefore fasciopathy.”

Second, the rehabilitation hierarchy. Manual therapy, taping, foot orthoses and stretching all receive moderate-evidence recommendations. High-load strength training receives a recommendation that is qualified but explicit. Dry needling, ultrasound and iontophoresis are downgraded or removed. Education on load management and expected timeframe (often six to twelve months for full resolution) is given more emphasis than in 2014.

Third, the guideline excludes pharmacological and surgical interventions except where directly compared to physical therapist management. That is a scope decision, not a clinical endorsement. The corticosteroid literature, summarised most clearly in David and colleagues’ Cochrane review, shows a small short-term analgesic benefit at one month that disappears by six and is associated with a non-trivial rupture risk.⁴ For the patient sitting in your room having had two injections in a year, the conversation about whether to repeat is now an evidence-informed conversation.

Pathomechanics: load, load, load

Wearing’s review remains the cleanest summary. The plantar fascia is a passive structure that, under load, stores and returns energy at the medial longitudinal arch. Strain peaks during late stance, when the toes dorsiflex over the metatarsal heads and the windlass mechanism is engaged. Repetitive tensile overload at the medial calcaneal enthesis exceeds the rate at which the fibroblasts in the fascia can repair the collagen matrix. The result is degenerative, not inflammatory.

What loads the fascia? Two contributions, summed. The windlass — passive, kinematic, driven by hallux dorsiflexion. And the Achilles — active, kinetic, driven by gastrocnemius and soleus contraction transmitted through the calcaneal periosteal continuity that Stecco and colleagues mapped in 2013.⁵ Their cadaveric dissection found the plantar fascia was more closely connected to the paratenon of the Achilles tendon than to the Achilles itself, via the periosteum of the heel. The fibres of the plantar fascia were continuous with the calcaneal periosteum and through it with the Achilles paratenon. This is a local fascial continuity, anatomically defensible regardless of how one feels about broader myofascial chain theories. The calf and the fascia share a tissue.

Carlson and colleagues, in their cadaveric simulation, showed that increasing Achilles tendon force increased plantar fascia strain in a linear fashion across the physiological range.⁶ Finite-element modelling (Cheng et al.) reproduces the finding: at the late stance position with the metatarsophalangeal joints dorsiflexed, Achilles tendon force is a major contributor to plantar fascia stress, comparable in magnitude to the windlass contribution.⁷

The clinical implication is the one this brand keeps making across the load-tolerance conditions — Achilles tendinopathy, plantar fasciopathy, medial tibial stress syndrome, Sever’s. A failing structure has an upstream load it cannot tolerate, and the upstream load is not coming from a single source. At the fascia, the calf is one of two main inputs. Treating the fascia in isolation — fascial stretching, fascial taping, fascial injection — addresses one tissue but ignores half the force driving it.

The soleus angle

Here is where this clinic disagrees with conventional rehabilitation. The soleus is the dominant plantarflexor at the slow walking and slow running velocities at which plantar fasciopathy patients live. It generates the bulk of Achilles tendon force across the stance phase of walking. The medial and lateral gastrocnemii contribute more in fast acceleration and jumping. For a deconditioned patient with chronic heel pain whose daily loading is walking and standing, the soleus is the structure transmitting most of the Achilles-derived force into the fascia.

Most plantar fasciopathy rehabilitation under-targets the soleus. The standard calf raise, performed in a knee-extended position, biases gastrocnemius. Wall stretches and standing fascial stretches similarly bias the biarticular muscle. The Rathleff protocol — about which more in a moment — has the right loading philosophy but is performed knee-extended in the original description, again favouring gastrocnemius.

A flexed-knee variant, bent-knee calf raises, with the same towel-under-toes setup, isolates soleus more effectively. We program both. The argument is not that gastrocnemius does not matter — it does, particularly in athletes returning to running. The argument is that the soleus is systematically underloaded, and that for the chronic walking-domain patient this matters.

The Rathleff protocol

Rathleff and Mølgaard’s 2015 RCT in Scandinavian Journal of Medicine & Science in Sports remains the cleanest piece of evidence we have for an exercise-first approach.⁸ Forty-eight patients with ultrasound-verified plantar fasciopathy were randomised to either plantar-specific stretching or high-load strength training. The strength protocol was unilateral heel raises with a rolled towel under the metatarsophalangeal joints, dorsiflexing the toes maximally at end-range. Three seconds concentric, two seconds isometric at top, three seconds eccentric. Three sets, every second day. Starting at 12RM, progressing to 8RM by week 8, then 6RM.

At three months, the strength group had a Foot Function Index 29 points lower than the stretch group — a clinically meaningful between-group difference. At six and twelve months the groups converged. The interpretation is that high-load strength training accelerates resolution but does not necessarily change the asymptote.

That is, for clinical purposes, important. Patients want to know how fast they will get better. The answer is: the natural history is favourable but slow, and loaded rehabilitation gets you there faster. It is the same story as patellar tendinopathy.

The towel detail is mechanistically lovely. Maximal hallux dorsiflexion at the top of the heel raise pre-loads the windlass, so the Achilles tension generated by the calf raise is transmitted through a fascia that is already under windlass tension. The fascia, in effect, is being trained at its in vivo loaded length.

Adjuncts: what is worth doing

Low-Dye taping reduces medial arch strain and produces modest short-term symptom reduction. Reasonable as a diagnostic test — does offloading the medial arch settle this person’s symptoms? if yes, orthoses are likely to help — and as a bridge while rehab takes hold. Not a stand-alone treatment.

Foot orthoses, prefabricated or custom, get a moderate recommendation in the 2023 CPG and a more positive nod from Whittaker and colleagues’ network meta-analysis.⁹ Both work; the cost-benefit case for custom over prefab is weak in most patients. Worth offering, particularly to patients with high BMI, sedentary occupations or shoes that offer no structural support.

Night splints: the evidence is mixed. Systematic reviews find low-quality evidence for symptom benefit, and the trials split. We use them selectively — chronic patients with severe first-step pain who have not responded to loading. The mechanism (overnight dorsiflexion preventing nocturnal shortening) is plausible; the trial data are not commanding.

Extracorporeal shockwave therapy: high-energy focused ESWT has reasonable evidence in chronic, recalcitrant cases. Babatunde and colleagues’ network meta-analysis in BJSM placed ESWT favourably for chronic presentations.¹⁰ Cost and access vary; reserve it for the patient who has done loaded rehab properly and remains stuck.

Corticosteroid injection: small short-term analgesic benefit at one month, no benefit at six, and a rupture risk that is small per injection but accumulates. Used sparingly, with full informed consent, in the patient whose pain is preventing engagement with rehabilitation. Not as a primary treatment. The previous era of routine quarterly injections has aged badly.

Differential vigilance

Three diagnoses get missed often enough to merit a permanent slot in the consultation.

Baxter’s nerve entrapment (first branch of the lateral plantar nerve). Maximal tenderness slightly distal and lateral to the classic plantar fascia insertion. Pain pattern is often worse with weight-bearing through the day rather than worst in the morning. No sensory deficit because Baxter’s is a motor branch. Suspect when the patient does not respond to load-based fascial rehab.

Calcaneal stress reaction. Adolescent runners, female runners with low energy availability, recent training spike. Squeeze test of the calcaneus is positive. MRI confirms. Cortisone here is harmful.

Tarsal tunnel syndrome. The great mimic. Look for sensory symptoms in the medial plantar nerve distribution, a positive Tinel at the medial ankle, and night pain that wakes the patient. Plantar fasciopathy night pain is unusual.

The 2023 CPG’s diagnostic flowchart formalises this screening. Worth printing.

Three patterns for clinical translation

For the acute, high-irritability patient — sharp first-step pain, sleep undisturbed, less than three months of symptoms — load modification plus Low-Dye taping plus isometric heel raises (5 x 45-second holds, mid-range, daily) to settle pain before progressing to the Rathleff protocol at week three or four. Counsel on natural history.

For the chronic, mid-irritability patient — six to twelve months of symptoms, has tried stretching and rest — full Rathleff protocol with knee-extended and bent-knee variants programmed in alternating sessions, prefabricated orthoses, removal of corticosteroid from the algorithm if it has been used recurrently. Realistic timeline: three to six months for meaningful change.

For the recalcitrant patient — over twelve months, failed loaded rehab, daily pain — re-examine the diagnosis (Baxter’s, fat pad, stress reaction), consider ESWT, and have a measured conversation about surgical options if all conservative routes have been adequately trialled.

The Sleeve as adjunct: addressing the ambulatory dose problem

The unspoken weakness of every plantar fasciopathy rehab plan is the dose problem outside the gym. The patient does her three-second-up, two-second-hold, three-second-down heel raises on the staircase three times a week. She also walks six to ten thousand steps a day. Every one of those steps is a windlass-loading event at the fascial enthesis. The Rathleff protocol works. Taping works for short-term symptom relief. Orthoses redistribute peak pressures. None of those interventions follow the patient home into the kitchen, the school pickup, the standing shift on the wards. The cumulative ambulatory dose is what keeps recalcitrant fasciopathy recalcitrant.

This is where the Orthopaedic Sleeve fits — as an adjunctive offload that travels with the patient through the day.

The UQ Final Report (June 2025) presents both group-level and individual-level findings, and clinicians should be precise about which is which. At the group level: medial gastrocnemius EMG during standing balance was reduced by 32% (p=0.002), modelled peak Achilles tendon force by 8.1%, and heel contact time during walking by 5.1% (p=0.009). The standing-balance EMG and walking heel-contact-time findings are statistically significant group effects. They are the ones to rely on when explaining the device to a patient or a colleague.

The late-stance walking calf EMG data reported maximal individual reductions of 47.8% for lateral gastrocnemius, 21.9% for medial gastrocnemius, and 20.4% for soleus. These are not group means. They are the largest individual responses observed during the dynamic gait window where the windlass mechanism and Achilles-derived fascial tension are co-loaded most heavily. Inter-individual variability is real and the lower end of the response distribution is closer to zero. Communicate this honestly — “in some participants, late-stance calf activation dropped by up to 47%” is defensible; “the Sleeve cuts your calf activity in half during walking” is not.

The mechanism that matters for fasciopathy is the convergence of these two effects on the upstream pulling force. Reduce heel contact time, and the fascia spends less cumulative time in the windlass-engaged position where strain peaks. Reduce gastrocnemius and soleus activation, and the Achilles-derived contribution to fascial tension drops in parallel. Both inputs to the fascia — the kinematic windlass and the kinetic calf pull — are quieter.

Position it to patients as the tool that gives your loading prescription room to actually work. The Rathleff protocol builds capacity. The Sleeve protects what is being built across the 95% of waking hours the patient is not in the gym. The same logic applies to the post-cortisone patient you are trying to wean off injection-led management, the recalcitrant case who has done loaded rehab properly but plateaued, and the patient with a non-modifiable standing-occupation load.

It is not a cure. It does not heal the fascia. Used the way Low-Dye taping is used — as a temporary offload during the slow rebuild — it has more wear-time and a more substantive biomechanical signature than tape, and it does not have to be reapplied every morning. That is the clinical place it occupies. A daily-wear adjunct to a load-based plan, not a substitute for it.